SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data ...

RESULTS IN HIGH VIRAL SUPPRESSION RATES IN UNTREATED HBEAG+ AND HBEAGSUBJECTS WITH CHRONIC HEPATITIS B OR CHRONIC HEPATITIS B ...

Understanding Hepatitis Viral hepatitis is a liver infection caused by different viruses (A, B, C, D, E). In India, it is a significant public health issue. As per ...

编者按在2024年美国肝病研究学会（AASLD）年会上，上海交通大学附属瑞金医院谢青教授团队的一项关于新型替诺福韦类药物——艾米替诺福韦（TMF）治疗ALT正常慢性HBV感染者的疗效和安全性研究 （PROMOTE）被大会收录，并进行了壁报交流（No.

Any person who might have a new sexual partner or use injection drugs is particularly recommended to get the hepatitis B ...

GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal ...

A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...

has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) and the Health and Disability Ethics Committees (HDEC) to initiate ...

Application error: a client-side exception has occurred (see the browser console for more information).

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA ...